Printer Friendly

MDL Announces Cooperative Research and Development Agreement with United States Food and Drug Administration.

TO: ASIAWIRE ATTN: EDITOR

Contact Name/Office: Wanda Glennon/SF Telephone: (415/986-4422) Fax: (415/788-5335) Email: newsroom@businesswire.com

Requested distribution time:

(X) For immediate release ( ) For future release, (please specify date and time):

_________________________________________________

PLEASE SELECT CIRCUIT OF CHOICE (BE SURE TO CHECK OFF IF TRANSLATION IS NEEDED)

NOTE TO ASIAWIRE: All translation requests (except Malay) will be handled through our vendor in Canada (Multi-Lingual Tek) and they will send the completed translations to you for distribution (in both Word and PDF formats). All releases will be sent directly to you first even when translation is requested so you will know that a translated release is expected.

!!**NOTE: IN THE REGIONAL CIRCUITS THAT REQUIRE TRANSLATIONS; SIMPLIFIED-PRC, TRADITIONAL HONG KONG AND KOREAN ARE THE DEFAULT TRANSLATIONS. BE SURE TO CHECK THEM OFF AT THE BOTTOM OF THE FORM. TRADITIONAL TAIWAN MAY BE SUBSTITUTED FOR EITHER THE SIMPLIFIED-PRC OR TRADITIONAL HONG KONG IF THE CLIENT REQUESTS IT.**!!

REGIONAL CIRCUITS:

( ) ALL ASIA PACIFIC FULL MEDIA (APFM)

(Including Translations into Simplified-PRC, Traditional

Hong Kong Chinese and Korean through Multi-Lingual Tek --

Be sure to check off appropriate language selections in the

Translations section of this form as well)

(XX ) All Asia Pacific Basic Media (APBM) (transmission in English)

( ) Asia Pacific AnalystWire (APAW) (transmission in English)

( ) All Asia Pacific Business Media

& High-Tech Trades (APHT) (transmission in English)

REGIONAL TRADES:

( ) Asia Pacific AutomotiveWire (APAU) ( ) Asia Pacific EnergyWire

(APEW) ( ) Asia Pacific EntertainmentWire (APEN) (XX) Asia Pacific HealthWire (APHW) ( ) Asia Pacific SportsWire

(APSW) ( ) All Asia High Tech Trades Only

OTHER REGIONAL TRADES:

( ) Asia Pacific Advertising/Marketing/Communications Trades ( ) Asia Pacific Electronics/Semiconductor Trades ( ) Asia Pacific Manufacturing Trades ( ) Asia Pacific Mining Trades ( ) Asia Pacific Telecommunications Trades ( ) Asia Pacific Transportation Trades ( ) Asia Pacific Travel Trades

OTHER COUNTRY-SPECIFIC TRADES:

( ) China High-Tech Trades ( ) China Medical Trades ( ) China Entertainment Trades ( ) China Sports Trades

( ) South Korea High-Tech Trades

CUSTOM:

( ) Asia Pacific Full distribution for Trend Micro Taiwan ( ) Asia Pacific Partial distribution for Trend Micro Taiwan

(excluding PRC-China and Korea) ( ) Custom distribution for McData (Business Wire/Denver client)

(includes translations into: Chinese -- simplified for PRC,

traditional for Hong Kong; Korean)

INDIVIDUAL COUNTRY CIRCUITS:

( ) CHINA ALL MEDIA (Incl. Translation)

(Make sure to check off Simplified-PRC Chinese under the

Translation section as well)

( ) HONG KONG BUSINESS MEDIA/HIGH-TECH TRADES (Incl. Translation)

(Make sure to check off Traditional-Hong Kong Chinese version

under the Translation section as well)

( ) SOUTH KOREA ALL MEDIA (Incl. Translation)

(Make sure to check off Korean under the Translation section

as well)

( ) MALAYSIA ALL MEDIA (Incl. Malay Translation) ( ) Singapore All Media (transmission in English) ( ) MALAYSIA/SINGAPORE ALL MEDIA (MSMT) (Incl. Malay Translation) ( ) MALAYSIA/SINGAPORE BUSINESS MEDIA

& HIGH-TECH TRADES (Incl. Malay Translation)

( ) Bangladesh All Media (transmission in English) ( ) Brunei All Media (transmission in English) ( ) Cambodia All Media

(transmission in English) ( ) India All Media (transmission in English) ( ) Indonesia All Media (transmission in English) ( ) Laos All Media (transmission in English) ( ) Myanmar All Media (transmission in English) ( ) Pakistan All Media

(transmission in English) ( ) Sri Lanka All Media (transmission in English) ( ) Thailand All Media (transmission in English) ( ) Vietnam All Media (transmission in English) ( ) Vietnam, Cambodia, & Laos (transmission in English)

====================================================================== SPECIAL INSTRUCTIONS: ==================== ____________________________________________________________________

____________________________________________________________________

====================================================================== ***BW EDITORS: IF TRANSLATION SERVICE REQUIRED: (for any language except Malay, which is handled by ASIAWIRE), Be sure to add the two email addresses (*info@mltek.com; *bw.asiatran@businesswire.com) to the [I line. This is very important***

TRANSLATION (Check off appropriate translations) ================================================ ( ) Translation approval required __________________________________

(NOTE TO MLTEK: If client requests translation approval, please

send a copy of any correspondence regarding the approval process

to trans.approval@businesswire.com for Business Wire's files)

[ ] CHINESE TRANSLATION FORTHCOMING - PROVIDED BY NORTH AMERICAN

AFFILIATE

(Business Wire Editors: If any Full-Text Chinese or Korean

translations ordered, be sure to check this box as well as the

languages selected - immediately below)

__Simplified-PRC __Traditional-Hong Kong (default) __Traditional-Taiwan (may be substituted for PRC or Hong Kong

upon client's request) ( ) Korean ( ) Malay (by Asiawire) ( ) TRANSLATION(S) INCLUDED - Specify which translations have been provided, and send via GroupWise as attachments to the addresses listed above.

NOTE TO MULTI-LINGUAL TEK: Once translations are completed, please send copies (with this form attached) to the following e-mail addresses:

translations@asiawire.info asiawire@tm.net.my bw.translations@businesswire.com bw.confirm@businesswire.com

-0-

Business Editors/Health/Medical Writers

SAN LEANDRO, Calif.--(BUSINESS WIRE)--July 10, 2003

Collaborative effort produces MDL(R) Carcinogenicity

Module for predicting a substance's carcinogenic potential

MDL Information Systems, Inc. (MDL(R)), the leader in discovery informatics for the life sciences and a member of the Elsevier Life Sciences division, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Food and Drug Administration (USFDA), Center for Drug Evaluation and Research (CDER). Under the terms of the CRADA, MDL and the USFDA will jointly develop a series of predictive software modules that represent major toxicological endpoints of interest to the regulatory agencies and the pharmaceutical industry. These endpoints are human adverse effects, carcinogenicity (ability to cause cancer), teratogenicity (ability to cause birth defects), and mutagenicity (ability to cause changes in genetic material).

The software modules will enable scientists in the pharmaceutical and biotechnology industries to identify and eliminate compounds with high potential for toxicity, such as those likely to be carcinogens, early in the drug discovery process. The ability to make better decisions earlier will accelerate the discovery of safer drugs, while also reducing animal testing.

The software is based on the MDL(R) QSAR platform, a comprehensive predictive modeling system that enables scientists to establish reliable quantitative structure-activity and structure-property relationships, create models for in silico screening, and generate new compound libraries based on the results.

The MDL(R) Carcinogenicity Module is the first module completed, and preliminary validation studies indicate that the MDL(R) QSAR modeling process, as performed by the USFDA, produces good estimates of a substance's carcinogenic potential. The module is based on historic data generated from rodent carcinogenicity studies that are used to predict the potential carcinogenic risk to humans. The predictive model does not require rodent studies to predict the human carcinogenic effect; it calculates a prediction based on chemical structure.

"Applying MDL QSAR's robust analysis capability to the USFDA toxicology databases creates powerful predictive models for the testing of drug candidates," said Lars Barfod, executive vice president and chief business officer of Elsevier Global Life Sciences Business. "This joint initiative underscores MDL's commitment to improving the predictive performance of computational toxicology software and enhancing decision support in both the regulatory and research domains."

The principal investigators for the USFDA are Dr. Joseph F. Contrera, Dr. Edwin J. Matthews, and Dr. R. Daniel Benz of the Informatics and Computational Safety Analysis Staff in the Office of Pharmaceutical Science. The MDL investigator is Philip M. MacLaughlin, product manager with the MDL(R) Discovery Predictive Science group.

MDL will make these toxicity modules, jointly created by MDL and the USFDA, available commercially to provide users with effective tools for the identification of potentially unsafe substances early in the discovery process. The MDL Carcinogenicity Module is available in July 2003.

About MDL

Over 1,000 life science companies supercharge their discovery engines with MDL software solutions to generate fresh ideas and make breakthrough discoveries. By synchronizing and streamlining the sharing and management of vital information and knowledge, we enable scientists to work more efficiently and invent drugs faster. This saves time, money, and lives. In support of our customers and the momentous challenges they face, everything we do must be reliable, resourceful, innovative, and insightful. We are an international business headquartered in San Leandro, CA with offices worldwide.

MDL is a member of Elsevier Life Sciences division, which combines all of Elsevier's life science content products with MDL's extensive informatics, database, workflow, and decision support solutions. The unique synergy between Elsevier's scientific and biomedical information and MDL's integrated discovery informatics software enables Elsevier Life Sciences to bring unparalleled solutions to researchers, significantly advancing the efficient, cost-effective development of new medicines. Elsevier is owned by Reed Elsevier PLC (NYSE: RUK) and Reed Elsevier NV (NYSE: ENL).

For more information, visit www.mdl.com.

MDL is a registered trademark in the United States of MDL Information Systems, Inc. "Powering the Process of Invention" is a trademark of MDL Information Systems, Inc., U.S. registration pending. Elsevier is a registered trademark in the United States of Reed Elsevier US Holdings Inc., and of Reed Elsevier NV in other countries. All other company and/or product names may be trademarks or registered trademarks of their respective owners in the United States and other countries. All rights reserved.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:9HONG
Date:Jul 10, 2003
Words:1419
Previous Article:Eastman CEO: Coal Gasification Long-Term Solution for Natural Gas Crisis.
Next Article:Advance Food Company Now Offers Vincello Lamb.


Related Articles
AIDS: education, testing continued.
Molecular Design Limited.
To join an MDL ... or not.
Expanded plan to combat mad cow disease. (EH Update).
IDT TO ACQUIRE RESEARCH UNIT.
MDL Provides UCB Pharma With Discovery Solutions to Power Global R&D Operations.
MDL Announces Cooperative Research and Development Agreement with United States Food and Drug Administration.
MDL Announces Cooperative Research and Development Agreement with United States Food and Drug Administration.
MDL and Inpharmatica Announce Reseller Agreement for Biopendium Database.
Elsevier MDL Unveils PharmaPendium(TM) -- A New Drug Safety Product.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters